Incyte Corp. (INCY)
121.70
-0.57
(-0.47%)
USD |
NASDAQ |
Nov 12, 16:00
121.72
+0.02
(+0.02%)
After-Hours: 20:00
Incyte Price to Book Value : 4.400 for Nov. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 4.400 |
| November 11, 2026 | 4.420 |
| November 10, 2026 | 4.349 |
| November 09, 2026 | 4.406 |
| November 06, 2026 | 4.326 |
| November 05, 2026 | 4.266 |
| November 04, 2026 | 4.441 |
| November 03, 2026 | 4.251 |
| November 02, 2026 | 4.340 |
| October 30, 2026 | 4.352 |
| October 29, 2026 | 4.222 |
| October 28, 2026 | 4.225 |
| October 27, 2026 | 4.215 |
| October 26, 2026 | 4.096 |
| October 23, 2026 | 4.183 |
| October 22, 2026 | 4.227 |
| October 21, 2026 | 4.101 |
| October 20, 2026 | 4.216 |
| October 19, 2026 | 4.094 |
| October 16, 2026 | 4.088 |
| October 15, 2026 | 4.095 |
| October 14, 2026 | 4.034 |
| October 13, 2026 | 3.927 |
| October 12, 2026 | 4.026 |
| October 09, 2026 | 4.078 |
| Date | Value |
|---|---|
| October 08, 2026 | 4.076 |
| October 07, 2026 | 4.101 |
| October 06, 2026 | 4.075 |
| October 05, 2026 | 4.126 |
| October 02, 2026 | 4.168 |
| October 01, 2026 | 4.235 |
| September 30, 2026 | 4.387 |
| September 29, 2026 | 3.903 |
| September 28, 2026 | 3.954 |
| September 25, 2026 | 3.925 |
| September 24, 2026 | 3.942 |
| September 23, 2026 | 3.948 |
| September 22, 2026 | 4.021 |
| September 21, 2026 | 3.949 |
| September 18, 2026 | 3.970 |
| September 17, 2026 | 4.043 |
| September 16, 2026 | 3.952 |
| September 15, 2026 | 3.856 |
| September 14, 2026 | 3.871 |
| September 11, 2026 | 3.848 |
| September 10, 2026 | 3.905 |
| September 09, 2026 | 3.992 |
| September 08, 2026 | 3.941 |
| September 04, 2026 | 4.015 |
| September 03, 2026 | 4.055 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 2.936 |
| Mirum Pharmaceuticals, Inc. | -- |
| AbbVie, Inc. | -- |
| Alnylam Pharmaceuticals, Inc. | 5.819 |
| Biogen, Inc. | 1.956 |
Price to Book Value Related Metrics
| PE Ratio | 64.76 |
| PS Ratio | 4.166 |
| Price to Free Cash Flow | 36.83 |
| Price | 121.70 |
| Earnings Yield | 1.54% |
| Market Cap | 24.83B |
| Operating PE Ratio | 35.72 |
| Normalized PE Ratio | 57.32 |